The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor β-induced Smad signaling in human ovarian cancer cells
- 17 October 2003
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 310 (2), 391-397
- https://doi.org/10.1016/j.bbrc.2003.09.021
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- How cells read TGF-β signalsNature Reviews Molecular Cell Biology, 2000
- Smads as transcriptional co-modulatorsCurrent Opinion in Cell Biology, 2000
- TGF-β signaling by Smad proteinsAdvances in Immunology, 2000
- Involvement of the p38 Mitogen-activated Protein Kinase Pathway in Transforming Growth Factor-β-induced Gene ExpressionOnline Journal of Public Health Informatics, 1999
- ATF-2 Is a Common Nuclear Target of Smad and TAK1 Pathways in Transforming Growth Factor-β SignalingOnline Journal of Public Health Informatics, 1999
- A Novel Kinase Cascade Mediated by Mitogen-activated Protein Kinase Kinase 6 and MKK3Online Journal of Public Health Informatics, 1996
- TAB1: An Activator of the TAK1 MAPKKK in TGF-β Signal TransductionScience, 1996
- Identification of a Member of the MAPKKK Family as a Potential Mediator of TGF-β Signal TransductionScience, 1995
- Identification of a Dual Specificity Kinase That Activates the Jun Kinases and p38-Mpk2Science, 1995
- Independent Human MAP-Kinase Signal Transduction Pathways Defined by MEK and MKK IsoformsScience, 1995